Epigenetics of dementia: understanding the disease as a transformation rather than a state

The Lancet Neurology

Volumn 15, Issue 7, 2016, Pages 760-774

  Maloney, Bryan ^a   Lahiri, Debomoy K ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DNA; HISTONE; MESSENGER RNA; MICRORNA;

CLINICAL TRIAL; DEMENTIA; DIET; ENVIRONMENTAL FACTOR; EPIGENETICS; GENOME-WIDE ASSOCIATION STUDY; HUMAN; MONOZYGOTIC TWINS; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; GENETIC EPIGENESIS;

DEMENTIA; EPIGENESIS, GENETIC; HUMANS;

EID: 84991507604     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(16)00065-X     Document Type: Review

References (169)

1. Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimers Dement 12 (2016), 459–509.
2. Erkinjuntti, T, Gauthier, S, The concept of vascular cognitive impairment. Front Neurol Neurosci 24 (2009), 79–85.
3. Hottman, DA, Chernick, D, Cheng, S, Wang, Z, Li, L, HDL and cognition in neurodegenerative disorders. Neurobiol Dis 72 (2014), 22–36.
4. Vann Jones, SA, O'Brien, JT, The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med 44 (2014), 673–683.
5. McCann, H, Stevens, CH, Cartwright, H, Halliday, GM, Alpha-synucleinopathy phenotypes. Parkinsonism Relat Disord 20:suppl 1 (2014), S62–S67.
6. Neumann, M, Sampathu, DM, Kwong, LK, et al. Ubiquitinated TDP43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314 (2006), 130–133.
7. Onyike, CU, Diehl-Schmid, J, The epidemiology of frontotemporal dementia. Int Rev Psychiatry 25 (2013), 130–137.
8. Wagner, L, Rechtman, L, Jordan, H, et al. State and metropolitan area-based amyotrophic lateral sclerosis (ALS) surveillance. Amyotroph Lateral Scler Frontotemporal Degener 17 (2015), 1–7.
9. Knopman, DS, Roberts, RO, Estimating the number of persons with frontotemporal lobar degeneration in the US population. J Mol Neurosci 45 (2011), 330–335.
10. Brenowitz, WD, Monsell, SE, Schmitt, FA, Kukull, WA, Nelson, PT, Hippocampal sclerosis of aging is a key Alzheimer's disease mimic: clinical-pathologic correlations and comparisons with both Alzheimer's disease and non-tauopathic frontotemporal lobar degeneration. J Alzheimers Dis 39 (2014), 691–702.
11. Kawas, CH, Kim, RC, Sonnen, JA, Bullain, SS, Trieu, T, Corrada, MM, Multiple pathologies are common and related to dementia in the oldest-old: the 90+ Study. Neurology 85 (2015), 535–542.
12. Crary, JF, Trojanowski, JQ, Schneider, JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 128 (2014), 755–766.
13. Attems, J, Neltner, JH, Nelson, PT, Quantitative neuropathological assessment to investigate cerebral multi-morbidity. Alzheimers Res Ther, 6, 2014, 85.
14. Prince, M, Bryce, R, Albanese, E, Wimo, A, Ribeiro, W, Ferri, CP, The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 9 (2013), 63–75.
15. Maloney, B, Sambamurti, K, Zawia, N, Lahiri, DK, Applying epigenetics to Alzheimer's disease via the latent early-life associated regulation (LEARn) model. Curr Alzheimer Res 9 (2012), 589–599.
16. Van Cauwenberghe, C, Van Broeckhoven, C, Sleegers, K, The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med, 2015 published online Aug 27. DOI:10.1038/gim.2015.117.
17. Cruts, M, Engelborghs, S, van der Zee, J, Van Broeckhoven, C, C9orf72-related amyotrophic lateral sclerosis and frontotemporal dementia. http://www.ncbi.nlm.nih.gov/books/NBK268647/, 1993 (accessed April 18, 2016).
18. T Cuenco, K, Lunetta, KL, Baldwin, CT, et al. Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease. Arch Neurol 65 (2008), 1640–1648.
19. Melville, SA, Buros, J, Parrado, AR, et al. Multiple loci influencing hippocampal degeneration identified by genome scan. Ann Neurol 72 (2012), 65–75.
20. Lill, CM, Roehr, JT, McQueen, MB, et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. PLoS Genet, 8, 2012, e1002548.
21. Nalls, MA, Pankratz, N, Lill, CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 46 (2014), 989–993.
22. Lill, CM, Abel, O, Bertram, L, Al-Chalabi, A, Keeping up with genetic discoveries in amyotrophic lateral sclerosis: the ALSoD and ALSGene databases. Amyotroph Lateral Scler 12 (2011), 238–249.
23. Bertram, L, McQueen, MB, Mullin, K, Blacker, D, Tanzi, RE, Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39 (2007), 17–23.
24. Bertram, L, McQueen, MB, Mullin, K, Blacker, D, Tanzi, RE, Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39 (2007), 17–23.
25. Schmidt, H, Freudenberger, P, Seiler, S, Schmidt, R, Genetics of subcortical vascular dementia. Exp Gerontol 47 (2012), 873–877.
26. Ning, M, Zhang, Z, Chen, Z, et al. Genetic evidence that vascular dementia is related to Alzheimer's disease: genetic association between tau polymorphism and vascular dementia in the Chinese population. Age Ageing 40 (2011), 125–128.
27. Petrucci, S, Ginevrino, M, Valente, EM, Phenotypic spectrum of alpha-synuclein mutations: new insights from patients and cellular models. Parkinsonism Relat Disord 22:suppl 1 (2016), S16–S20.
28. Ohtake, H, Limprasert, P, Fan, Y, et al. Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 63 (2004), 805–811.
29. Gorostidi, A, Bergareche, A, Ruiz-Martinez, J, et al. Alpha-synuclein levels in blood plasma from LRRK2 mutation carriers. PLoS One, 7, 2012, e52312.
30. Hall, K, Murrell, J, Ogunniyi, A, et al. Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba. Neurology 66 (2006), 223–227.
31. Brickell, KL, Leverenz, JB, Steinbart, EJ, et al. Clinicopathological concordance and discordance in three monozygotic twin pairs with familial Alzheimer's disease. J Neurol Neurosurg Psychiatry 78 (2007), 1050–1055.
32. Iacono, D, Volkman, I, Nennesmo, I, et al. Neuropathologic assessment of dementia markers in identical and fraternal twins. Brain Pathol 24 (2014), 317–333.
33. Chouliaras, L, Mastroeni, D, Delvaux, E, et al. Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer's disease patients. Neurobiol Aging 34 (2013), 2091–2099.
34. Ketelaar, ME, Hofstra, EM, Hayden, MR, What monozygotic twins discordant for phenotype illustrate about mechanisms influencing genetic forms of neurodegeneration. Clin Genet 81 (2012), 325–333.
35. Mastroeni, D, McKee, A, Grover, A, Rogers, J, Coleman, PD, Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease. PLoS One, 4, 2009, e6617.
36. Woodard, CM, Campos, BA, Kuo, SH, et al. iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's disease. Cell Rep 9 (2014), 1173–1182.
37. Wang, CS, Burke, JR, Steffens, DC, Hulette, CM, Breitner, JC, Plassman, BL, Twin pairs discordant for neuropathologically confirmed Lewy body dementia. J Neurol Neurosurg Psychiatry 80 (2009), 562–565.
38. Meltz Steinberg, K, Nicholas, TJ, Koboldt, DC, Yu, B, Mardis, E, Pamphlett, R, Whole genome analyses reveal no pathogenetic single nucleotide or structural differences between monozygotic twins discordant for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 16 (2015), 1–8.
39. Yip, AG, Green, RC, Huyck, M, Cupples, LA, Farrer, LA, Group, MS, Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study. BMC Geriatr, 5, 2005, 2.
40. Perneczky, R, Wagenpfeil, S, Lunetta, KL, et al. Education attenuates the effect of medial temporal lobe atrophy on cognitive function in Alzheimer's disease: the MIRAGE study. J Alzheimers Dis 17 (2009), 855–862.
41. Yang, ST, Hsiao, IT, Hsieh, CJ, et al. Accumulation of amyloid in cognitive impairment after mild traumatic brain injury. J Neurol Sci 349 (2015), 99–104.
42. Rockenstein, E, Nuber, S, Overk, CR, et al. Accumulation of oligomer-prone alpha-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain 137 (2014), 1496–1513.
43. Mattsson, N, Insel, PS, Nosheny, R, et al. Emerging beta-amyloid pathology and accelerated cortical atrophy. JAMA Neurol 71 (2014), 725–734.
44. Lee, G, Leugers, CJ, Tau and tauopathies. Prog Mol Biol Transl Sci 107 (2012), 263–293.
45. Hamidi, T, Singh, AK, Chen, T, Genetic alterations of DNA methylation machinery in human diseases. Epigenomics 7 (2015), 247–265.
46. Kouzarides, T, Chromatin modifications and their function. Cell 128 (2007), 693–705.
47. Al-Mahdawi, S, Virmouni, SA, Pook, MA, The emerging role of 5-hydroxymethylcytosine in neurodegenerative diseases. Front Neurosci, 8, 2014, 397.
48. Zawia, NH, Lahiri, DK, Cardozo-Pelaez, F, Epigenetics, oxidative stress, and Alzheimer disease. Free Radic Biol Med 46 (2009), 1241–1249.
49. Hendrickx, A, Pierrot, N, Tasiaux, B, et al. Epigenetic regulations of immediate early genes expression involved in memory formation by the amyloid precursor protein of Alzheimer disease. PLoS One, 9, 2014, e99467.
50. Wang, BY, Zhong, Y, Zhao, Z, Miao, Y, Epigenetic suppression of hippocampal BDNF mediates the memory deficiency induced by amyloid fibrils. Pharmacol Biochem Behav 126 (2014), 83–89.
51. Noh, H, Seo, H, Age-dependent effects of valproic acid in Alzheimer's disease (AD) mice are associated with nerve growth factor (NGF) regulation. Neuroscience 266 (2014), 255–265.
52. Yasui, DH, Peddada, S, Bieda, MC, et al. Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes. Proc Natl Acad Sci USA 104 (2007), 19416–19421.
53. Zelko, IN, Mueller, MR, Folz, RJ, CpG methylation attenuates Sp1 and Sp3 binding to the human extracellular superoxide dismutase promoter and regulates its cell-specific expression. Free Radic Biol Med 48 (2010), 895–904.
54. Dosunmu, R, Wu, J, Adwan, L, et al. Lifespan profiles of Alzheimer's disease-associated genes and products in monkeys and mice. J Alzheimers Dis 18 (2009), 211–230.
55. Cohen, S, Gabel, HW, Hemberg, M, et al. Genome-wide activity-dependent MeCP2 phosphorylation regulates nervous system development and function. Neuron 72 (2011), 72–85.
56. Valinluck, V, Tsai, HH, Rogstad, DK, Burdzy, A, Bird, A, Sowers, LC, Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Res 32 (2004), 4100–4108.
57. Jacob, KD, Noren Hooten, N, Tadokoro, T, Lohani, A, Barnes, J, Evans, MK, Alzheimer's disease-associated polymorphisms in human OGG1 alter catalytic activity and sensitize cells to DNA damage. Free Radic Biol Med 63 (2013), 115–125.
58. Rusiecki, JA, Baccarelli, A, Bollati, V, et al. Global DNA hypomethylation is associated with high serum-persistent organic pollutants in Greenlandic Inuit. Environ Health Perspect 116 (2008), 1547–1552.
59. Kim, KY, Kim, DS, Lee, SK, et al. Association of low-dose exposure to persistent organic pollutants with global DNA hypomethylation in healthy Koreans. Environ Health Perspect 118 (2010), 370–374.
60. Zhao, M, Wang, LT, Liang, GP, et al. Up-regulation of microRNA-210 induces immune dysfunction via targeting FOXP3 in CD4(+) T cells of psoriasis vulgaris. Clin Immunol 150 (2014), 22–30.
61. Shaw, KT, Utsuki, T, Rogers, J, et al. Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci U S A 98 (2001), 7605–7610.
62. Long, JM, Ray, B, Lahiri, DK, MicroRNA-339-5p down-regulates protein expression of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects. J Biol Chem 289 (2014), 5184–5198.
63. Evans, RM, Hui, S, Perkins, A, Lahiri, DK, Poirier, J, Farlow, MR, Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology 62 (2004), 1869–1871.
64. Holtzman, DM, Herz, J, Bu, G, Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med, 2, 2012, a006312.
65. Verghese, PB, Castellano, JM, Garai, K, et al. ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Proc Natl Acad Sci USA 110 (2013), E1807–E1816.
66. Rasmussen, KL, Tybjaerg-Hansen, A, Nordestgaard, BG, Frikke-Schmidt, R, Plasma levels of apolipoprotein E and risk of dementia in the general population. Ann Neurol 77 (2015), 301–311.
67. Yu, CE, Cudaback, E, Foraker, J, et al. Epigenetic signature and enhancer activity of the human APOE gene. Hum Mol Genet 22 (2013), 5036–5047.
68. Tartaglione, AM, Venerosi, A, Calamandrei, G, Early-life toxic insults and onset of sporadic neurodegenerative diseases—an overview of experimental studies. Curr Top Behav Neurosci, 2015 published online Dec 23. DOI:10.1007/7854_2015_416.
69. Bekkering, S, Joosten, LA, van der Meer, JW, Netea, MG, Riksen, NP, The epigenetic memory of monocytes and macrophages as a novel drug target in atherosclerosis. Clin Ther 37 (2015), 914–923.
70. Brown, R, Curry, E, Magnani, L, Wilhelm-Benartzi, CS, Borley, J, Poised epigenetic states and acquired drug resistance in cancer. Nat Rev Cancer 14 (2014), 747–753.
71. Zager, RA, ‘Biologic memory’ in response to acute kidney injury: cytoresistance, toll-like receptor hyper-responsiveness and the onset of progressive renal disease. Nephrol Dial Transplant 28 (2013), 1985–1993.
72. Comer, BS, Ba, M, Singer, CA, Gerthoffer, WT, Epigenetic targets for novel therapies of lung diseases. Pharmacol Ther 147 (2015), 91–110.
73. Montalvo-Ortiz, JL, Keegan, J, Gallardo, C, et al. HDAC inhibitors restore the capacity of aged mice to respond to haloperidol through modulation of histone acetylation. Neuropsychopharmacology 39 (2014), 1469–1478.
74. Hardy, J, The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 110 (2009), 1129–1134.
75. Nabuurs, RJ, Natte, R, de Ronde, FM, et al. MR microscopy of human amyloid-beta deposits: characterization of parenchymal amyloid, diffuse plaques, and vascular amyloid. J Alzheimers Dis 34 (2013), 1037–1049.
76. Snyder, HM, Corriveau, RA, Craft, S, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement 11 (2015), 710–717.
77. Kast, J, Hanecker, P, Beaufort, N, et al. Sequestration of latent TGF-beta binding protein 1 into CADASIL-related Notch3-ECD deposits. Acta Neuropathol Comm, 2, 2014, 96.
78. Bodles, AM, Irvine, GB, Alpha-synuclein aggregation. Protein Peptide Lett 11 (2004), 271–279.
79. Delacourte, A, Tauopathies: recent insights into old diseases. Folia Neuropathol 43 (2005), 244–257.
80. Lalmansingh, AS, Urekar, CJ, Reddi, PP, TDP-43 is a transcriptional repressor: the testis-specific mouse acrv1 gene is a TDP-43 target in vivo. J Biol Chem 286 (2011), 10970–10982.
81. Arai, T, Mackenzie, IR, Hasegawa, M, et al. Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol 117 (2009), 125–136.
82. Nelson, PT, Smith, CD, Abner, EL, et al. Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease. Acta Neuropathol 126 (2013), 161–177.
83. Gavett, BE, Stern, RA, McKee, AC, Chronic traumatic encephalopathy: a potential late effect of sport-related concussive and subconcussive head trauma. Clin Sports Med 30 (2011), 179–188.
84. Tian, T, Huang, C, Tong, J, Yang, M, Zhou, H, Xia, XG, TDP-43 potentiates alpha-synuclein toxicity to dopaminergic neurons in transgenic mice. Int J Biol Sci 7 (2011), 234–243.
85. Nakashima-Yasuda, H, Uryu, K, Robinson, J, et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 114 (2007), 221–229.
86. Chauhan, A, Chauhan, VP, Brockerhoff, H, Wisniewski, HM, Action of amyloid beta-protein on protein kinase C activity. Life Sci 49 (1991), 1555–1562.
87. Kontopoulos, E, Parvin, JD, Feany, MB, Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 15 (2006), 3012–3023.
88. Ding, H, Dolan, PJ, Johnson, GV, Histone deacetylase 6 interacts with the microtubule-associated protein tau. J Neurochem 106 (2008), 2119–2130.
89. Fiesel, FC, Voigt, A, Weber, SS, et al. Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6. EMBO J 29 (2010), 209–221.
90. Dubois, B, Feldman, HH, Jacova, C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 13 (2014), 614–629.
91. Migliore, L, Coppede, F, Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat Res 667 (2009), 82–97.
92. Lee, EB, Mattson, MP, The neuropathology of obesity: insights from human disease. Acta Neuropathol 127 (2014), 3–28.
93. Vanitallie, TB, Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention. Metabolism 62:suppl 1 (2013), S30–S33.
94. Morris, MC, Tangney, CC, Dietary fat composition and dementia risk. Neurobiol Aging 35:suppl 2 (2014), S59–S64.
95. Treiber, KA, Carlson, MC, Corcoran, C, et al. Cognitive stimulation and cognitive and functional decline in Alzheimer's disease: the cache county dementia progression study. J Gerontol B Psychol Sci Soc Sci 66 (2011), 416–425.
96. Okonkwo, OC, Schultz, SA, Oh, JM, et al. Physical activity attenuates age-related biomarker alterations in preclinical AD. Neurology 83 (2014), 1753–1760.
97. Tian, Q, Glynn, NW, Erickson, KI, et al. Objective measures of physical activity, white matter integrity and cognitive status in adults over age 80. Behav Brain Res 284 (2015), 51–57.
98. Cohen, E, Bieschke, J, Perciavalle, RM, Kelly, JW, Dillin, A, Opposing activities protect against age-onset proteotoxicity. Science 313 (2006), 1604–1610.
99. Song, C, Kanthasamy, A, Anantharam, V, Sun, F, Kanthasamy, AG, Environmental neurotoxic pesticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: relevance to epigenetic mechanisms of neurodegeneration. Mol Pharmacol 77 (2010), 621–632.
100. Baltazar, MT, Dinis-Oliveira, RJ, de Lourdes Bastos, M, Tsatsakis, AM, Duarte, JA, Carvalho, F, Pesticides exposure as etiological factors of Parkinson's disease and other neurodegenerative diseases—a mechanistic approach. Toxicol Lett 230 (2014), 85–103.
101. Lin, JN, Lin, CL, Lin, MC, et al. Increased risk of dementia in patients with acute organophosphate and carbamate poisoning: a nationwide population-based cohort study. Medicine (Baltimore), 94, 2015, e1187.
102. Klimentidis, YC, Beasley, TM, Lin, HY, et al. Canaries in the coal mine: a cross-species analysis of the plurality of obesity epidemics. Proc Biol Sci 278 (2011), 1626–1632.
103. Condliffe, D, Wong, A, Troakes, C, et al. Cross-region reduction in 5-hydroxymethylcytosine in Alzheimer's disease brain. Neurobiol Aging 35 (2014), 1850–1854.
104. De Jager, PL, Srivastava, G, Lunnon, K, et al. Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat Neurosci 17 (2014), 1156–1163.
105. Yu, L, Chibnik, LB, Srivastava, GP, et al. Association of brain DNA methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4, and BIN1 with pathological diagnosis of Alzheimer disease. JAMA Neurol 72 (2015), 15–24.
106. Sanchez-Mut, JV, Aso, E, Heyn, H, et al. Promoter hypermethylation of the phosphatase DUSP22 mediates PKA-dependent TAU phosphorylation and CREB activation in Alzheimer's disease. Hippocampus 24 (2014), 363–368.
107. Belzil, VV, Bauer, PO, Gendron, TF, Murray, ME, Dickson, D, Petrucelli, L, Characterization of DNA hypermethylation in the cerebellum of c9FTD/ALS patients. Brain Res 1584 (2014), 15–21.
108. Belzil, VV, Bauer, PO, Prudencio, M, et al. Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol 126 (2013), 895–905.
109. Wirdefeldt, K, Gatz, M, Schalling, M, Pedersen, NL, No evidence for heritability of Parkinson disease in Swedish twins. Neurology 63 (2004), 305–311.
110. Zhang, L, Sheng, S, Qin, C, The role of HDAC6 in Alzheimer's disease. J Alzheimers Dis 33 (2013), 283–295.
111. Jowaed, A, Schmitt, I, Kaut, O, Wullner, U, Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. J Neurosci 30 (2010), 6355–6359.
112. Du, Y, Wang, F, Zou, J, et al. Histone deacetylase 6 regulates cytotoxic alpha-synuclein accumulation through induction of the heat shock response. Neurobiol Aging 35 (2014), 2316–2328.
113. Coupland, KG, Mellick, GD, Silburn, PA, et al. DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E in vitro. Mov Disord 29 (2014), 1606–1614.
114. Kikuchi, Y, Yasuhara, T, Agari, T, et al. Urinary 8-OHdG elevations in a partial lesion rat model of Parkinson's disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion. J Cell Physiol 226 (2011), 1390–1398.
115. Desai, M, Jellyman, JK, Ross, MG, Epigenomics, gestational programming and risk of metabolic syndrome. Int J Obes (Lond) 39 (2015), 633–641.
116. Panza, F, Frisardi, V, Capurso, C, et al. Metabolic syndrome and cognitive impairment: current epidemiology and possible underlying mechanisms. J Alzheimers Dis 21 (2010), 691–724.
117. Van den Hove, DL, Kompotis, K, Lardenoije, R, et al. Epigenetically regulated microRNAs in Alzheimer's disease. Neurobiol Aging 35 (2014), 731–745.
118. Hodgson, N, Trivedi, M, Muratore, C, Li, S, Deth, R, Soluble oligomers of amyloid-beta cause changes in redox state, DNA methylation, and gene transcription by inhibiting EAAT3 mediated cysteine uptake. J Alzheimers Dis 36 (2013), 197–209.
119. Dominissini, D, Genomics and proteomics. Roadmap to the epitranscriptome. Science, 346, 2014, 1192.
120. Sandve, GK, Gundersen, S, Rydbeck, H, et al. The differential disease regulome. BMC Genomics, 12, 2011, 353.
121. Krebs, JE, Goldstein, ES, Kilpatrick, ST, Lewin's genes XI, 2016, Jones & Bartlett Learning, Burlington MA.
122. Nonne, N, Ameyar-Zazoua, M, Souidi, M, Harel-Bellan, A, Tandem affinity purification of miRNA target mRNAs (TAP-Tar). Nucleic Acids Res, 38, 2010, e20.
123. Baek, D, Villen, J, Shin, C, Camargo, FD, Gygi, SP, Bartel, DP, The impact of microRNAs on protein output. Nature 455 (2008), 64–71.
124. Aavik, E, Lumivuori, H, Leppanen, O, et al. Global DNA methylation analysis of human atherosclerotic plaques reveals extensive genomic hypomethylation and reactivation at imprinted locus 14q32 involving induction of a miRNA cluster. Eur Heart J 36 (2015), 993–1000.
125. Xie, T, Liang, J, Guo, R, Liu, N, Noble, PW, Jiang, D, Comprehensive microRNA analysis in bleomycin-induced pulmonary fibrosis identifies multiple sites of molecular regulation. Physiol Genomics 43 (2011), 479–487.
126. Spencer, P, Fry, RC, Kisby, GE, Unraveling 50-year-old clues linking neurodegeneration and cancer to cycad toxins: are micrornas common mediators?. Front Genet, 3, 2012, 192.
127. Piaceri, I, Raspanti, B, Tedde, A, Bagnoli, S, Sorbi, S, Nacmias, B, Epigenetic modifications in Alzheimer's disease: cause or effect?. J Alzheimers Dis 43 (2015), 1169–1173.
128. Dias, BG, Ressler, KJ, Parental olfactory experience influences behavior and neural structure in subsequent generations. Nat Neurosci 17 (2014), 89–96.
129. Reis, AH, Vargas, FR, Lemos, B, More epigenetic hits than meets the eye: microRNAs and genes associated with the tumorigenesis of retinoblastoma. Front Genet, 3, 2012, 284.
130. Bihaqi, SW, Schumacher, A, Maloney, B, Lahiri, DK, Zawia, NH, Do epigenetic pathways initiate late onset Alzheimer disease (LOAD): towards a new paradigm. Curr Alzheimer Res 9 (2012), 574–588.
131. Zarin, DA, Tse, T, Sheehan, J, The proposed rule for U.S. clinical trial registration and results submission. N Engl J Med 372 (2015), 174–180.
132. Lahiri, DK, Sokol, DK, Erickson, C, Ray, B, Ho, CY, Maloney, B, Autism as early neurodevelopmental disorder: evidence for an sAPPalpha-mediated anabolic pathway. Front Cell Neurosci, 7, 2013, 94.
133. Caraci, F, Leggio, GM, Drago, F, Salomone, S, Epigenetic drugs for Alzheimer's disease: hopes and challenges. Br J Clin Pharmacol 75 (2013), 1154–1155.
134. Baierle, M, Vencato, PH, Oldenburg, L, et al. Fatty acid status and its relationship to cognitive decline and homocysteine levels in the elderly. Nutrients 6 (2014), 3624–3640.
135. Huang, T, Zheng, J, Chen, Y, et al. High consumption of Ω-3 polyunsaturated fatty acids decrease plasma homocysteine: a meta-analysis of randomized, placebo-controlled trials. Nutrition 27 (2011), 863–867.
136. Ray, B, Bisht, S, Maitra, A, Maitra, A, Lahiri, DK, Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc) in the neuronal cell culture and animal model: implications for Alzheimer's disease. J Alzheimers Dis 23 (2011), 61–77.
137. Gupta, SC, Patchva, S, Aggarwal, BB, Therapeutic roles of curcumin: lessons learned from clinical trials. AAPSJ 15 (2013), 195–218.
138. Shu, L, Khor, TO, Lee, JH, et al. Epigenetic CpG demethylation of the promoter and reactivation of the expression of Neurog1 by curcumin in prostate LNCaP cells. AAPSJ 13 (2011), 606–614.
139. Smith, PJ, Blumenthal, JA, Babyak, MA, et al. Effects of the dietary approaches to stop hypertension diet, exercise, and caloric restriction on neurocognition in overweight adults with high blood pressure. Hypertension 55 (2010), 1331–1338.
140. Lahiri, DK, Maloney, B, Long, JM, Greig, NH, Lessons from a BACE1 inhibitor trial: off-site but not off base. Alzheimers Dementia 10:suppl (2014), S411–S419.
141. Evans, GW, Schamberg, MA, Childhood poverty, chronic stress, and adult working memory. Proc Natl Acad Sci USA 106 (2009), 6545–6549.
142. Dias-Ferreira, E, Sousa, JC, Melo, I, et al. Chronic stress causes frontostriatal reorganisation and affects decision-making. Science 325 (2009), 621–625.
143. Van Vliet, J, Oates, NA, Whitelaw, E, Epigenetic mechanisms in the context of complex diseases. Cell Mol Life Sci 64 (2007), 1531–1538.
144. Vucetic, Z, Kimmel, J, Reyes, TM, Chronic high-fat diet drives postnatal epigenetic regulation of mu-opioid receptor in the brain. Neuropsychopharmacology 36 (2011), 1199–1206.
145. Lahiri, DK, Maloney, B, The “LEARn” (latent early-life associated regulation) model integrates environmental risk factors and the developmental basis of Alzheimer's disease, and proposes remedial steps. Exp Gerontol 45 (2010), 291–296.
146. Chan, A, Shea, TB, Supplementation with apple juice attenuates presenilin-1 overexpression during dietary and genetically-induced oxidative stress. J Alzheimers Dis 10 (2006), 353–358.
147. Chan, A, Remington, R, Kotyla, E, Lepore, A, Zemianek, J, Shea, TB, A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia. J Nutr Health Aging 14 (2010), 224–230.
148. Wengreen, H, Munger, RG, Cutler, A, et al. Prospective study of Dietary Approaches to Stop Hypertension and Mediterranean-style dietary patterns and age-related cognitive change: the Cache County Study on Memory, Health and Aging. Am J Clin Nutr 98 (2013), 1263–1271.
149. Rigacci, S, Olive oil phenols as promising multi-targeting agents against Alzheimer's disease. Adv Exp Med Biol 863 (2015), 1–20.
150. Corella, D, Ordovas, JM, How does the Mediterranean diet promote cardiovascular health? Current progress toward molecular mechanisms: gene–diet interactions at the genomic, transcriptomic, and epigenomic levels provide novel insights into new mechanisms. Bioessays 36 (2014), 526–537.
151. Montgomery, SE, Sepehry, AA, Wangsgaard, JD, Koenig, JE, The effect of S-adenosylmethionine on cognitive performance in mice: an animal model meta-analysis. PLoS One, 9, 2014, e107756.
152. Ghosh, S, Yates, AJ, Fruhwald, MC, Miecznikowski, JC, Plass, C, Smiraglia, D, Tissue specific DNA methylation of CpG islands in normal human adult somatic tissues distinguishes neural from non-neural tissues. Epigenetics 5 (2010), 527–538.
153. Bjornsson, HT, Sigurdsson, MI, Fallin, MD, et al. Intra-individual change over time in DNA methylation with familial clustering. JAMA 299 (2008), 2877–2883.
154. Nasrallah, HA, Hopkins, T, Pixley, SK, Differential effects of antipsychotic and antidepressant drugs on neurogenic regions in rats. Brain Res 1354 (2010), 23–29.
155. Marioni, RE, Shah, S, McRae, AF, et al. DNA methylation age of blood predicts all-cause mortality in later life. Genome Biol, 16, 2015, 25.
156. Fraga, MF, Ballestar, E, Paz, MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 102 (2005), 10604–10609.
157. Ottini, L, Rizzolo, P, Siniscalchi, E, et al. Gene promoter methylation and DNA repair capacity in monozygotic twins with discordant smoking habits. Mutat Res Genet Toxicol Environ Mutagen 779 (2015), 57–64.
158. Murgatroyd, C, Patchev, AV, Wu, Y, et al. Dynamic DNA methylation programs persistent adverse effects of early-life stress. Nat Neurosci 12 (2009), 1559–1566.
159. Lu, T, Pan, Y, Kao, SY, et al. Gene regulation and DNA damage in the ageing human brain. Nature 429 (2004), 883–891.
160. Radak, Z, Kaneko, T, Tahara, S, et al. Regular exercise improves cognitive function and decreases oxidative damage in rat brain. Neurochem Int 38 (2001), 17–23.
161. Basha, MR, Wei, W, Bakheet, SA, et al. The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J Neurosci 25 (2005), 823–829.
162. Wu, J, Basha, MR, Brock, B, et al. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci 28 (2008), 3–9.
163. Lahiri, DK, Maloney, B, Zawia, NH, The LEARn model: an epigenetic explanation for idiopathic neurobiological diseases. Mol Psychiatry 14 (2009), 992–1003.
164. Lahiri, DK, Maloney, B, Gene x environment interaction by a longitudinal epigenome-wide association study (LEWAS) overcomes limitations of genome-wide association study (GWAS). Epigenomics 4 (2012), 685–699.
165. Jackson, F, Jackson, L, Cross, C, Clarke, C, What could you do with 400 years of biological history on African Americans? Evaluating the potential scientific benefit of systematic studies of dental and skeletal materials on African Americans from the 17th through 20th centuries. Am J Hum Biol, 2016 published online Jan 9. DOI:10.1002/ajhb.22821.
166. Vradenburg, G, Probing the realities of big data in Alzheimer's. http://www.usagainstalzheimers.org/blog/probing-realities-big-data-alzheimers#sthash.IndnImzH.dpuf (accessed April 18, 2016).
167. Berndt, SI, Camp, NJ, Skibola, CF, et al. Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nat Commun, 7, 2016, 10933.
168. Sage Bionetworks. Alzheimer's disease big data DREAM challenge 1. www.synapse.org/#!Synapse:syn2290704 (accessed April 18, 2016).
169. Gomez-Pinilla, F, Zhuang, Y, Feng, J, Ying, Z, Fan, G, Exercise impacts brain-derived neurotrophic factor plasticity by engaging mechanisms of epigenetic regulation. Eur J Neurosci 33 (2011), 383–390.